

BIOSPECIFICS TECHNOLOGIES CORP  
Form NT 10-K  
March 18, 2019

---

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

SEC FILE  
NUMBER  
001-34236

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

CUSIP NUMBER  
090931106

*(Check one):*

☒ Form 10-K    ☐ Form 20-F    ☐ Form 11-K  
☐ Form 10-Q    ☐ Form 10-D    ☐ Form N-SAR    ☐ Form N-CSR

For Period Ended: December 31, 2018

☐ Transition Report on Form 10-K  
☐ Transition Report on Form 20-F  
☐ Transition Report on Form 11-K  
☐ Transition Report on Form 10-Q  
☐ Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
---

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I REGISTRANT INFORMATION**

**BioSpecifics Technology Corp.**

Full Name of Registrant

**Not Applicable**

Former Name if Applicable

**35 Wilbur Street**

Address of Principal Executive Office (*Street and Number*)

**Lynbrook, NY 11563**  
City, State and Zip Code

---

**PART II RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

**BioSpecifics Technologies Corp. (the "Company" is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the period ended December 31, 2018 (the "Form 10-K"). The Company has determined that it is unable to file its Form 10-K within the prescribed time period provided by the applicable rules of the Securities and Exchange Commission without unreasonable effort and expense because it requires additional time to finalize its disclosures to be made as part of the Form 10-K as it completes its year-end closing process. The Company announced on March 18, 2019 the death of Tom Wegman, its Principal Executive Officer and Principal Financial/Accounting Officer, on March 13, 2019. The Company requires more time to complete the appointment of the new Principal Executive Officer and Principal Financial/Accounting Officer. The Company plans to file its Form 10-K no later than the fifteenth calendar day after its prescribed due date.**

**PART IV OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification

**Carl A. Valenstein**

(Name)

**617**

(Area Code)

**341-7501**

(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

[ x ] Yes [ ] No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

[ ] Yes [ x ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**BioSpecifics Technologies Corp.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2019

By: */s/ Carl A. Valenstein*

Carl A. Valenstein

Title: Corporate Secretary

---